TITLE:
Excision Repair Cross-Complementation Group 1 (ERCC1): A Prognostic and Predictive Biomarker in Patients with Colorectal Cancer Receiving Adjuvant Oxaliplatin Based Chemotherapy
AUTHORS:
Adel Gabr, T. M. Elsaba, Khalid Razek, Shaima Tamam, Haisam Atta
KEYWORDS:
ERCC1, CRC, Oxaliplatin, IH
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.9,
September
1,
2016
ABSTRACT: Background:
Colorectal cancer (CRC) ranks as the third most common cancer and the third
most killing cancer worldwide [1]. The addition of oxaliplatin to fluorouracil (FOLFOX) or capecitabine (CAPOX)
has become a fundamental component of chemotherapeutic regimens and
chemoradiation in adjuvant treatment of CRC cancer. Excision repair
cross-complementation group 1 (ERCC1) encodes an enzyme that is essential for
the efficient repair of DNA damage induced by platinum compounds including
Oxaliplatin. Purpose: This study
aims to
investigate the role of ERCC1 as a predictive and prognostic marker in
colorectal patients receiving oxaliplatin based chemotherapy and
chemoradiation. Patients and Methods: 100
annotated stage
III CRC patients were prepared as immunohistochemical (IHC)
analysis of ERCC1 protein expression. All of the patients received oxaliplatin
based chemotherapy. Results: Analysis of data showed that high ERCC1 expression was
significantly associated with early treatment failure and disease free survival
among patient with stage III CRC. Conclusion: High ERCC1 expression was an
independent predictor factor of early treatment failure (P = 0.004).